# Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans

> **NCT00243191** · PHASE2 · COMPLETED · sponsor: **Sarcoma Alliance for Research through Collaboration** · enrollment: 18 (actual)

## Conditions studied

- Dermatofibrosarcoma Protuberans

## Interventions

- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00243191
- **Lead sponsor:** Sarcoma Alliance for Research through Collaboration
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2012-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00243191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00243191, "Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00243191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*